Transcatheter Tricuspid Valve Replacement
Sponsors
Edwards Lifesciences, Trisol Medical, Montefiore Medical Center, TRiCares, inQB8 Medical Technologies, LLC
Conditions
Cardiovascular DiseasesHeart Valve DiseaseHeart Valve DiseasesHigh-surgical Risk Patients with Severe Tricuspid RegurgitationTranscatheter Valve ReplacementTricuspid RegurgitationTricuspid Regurgitation (TR)Tricuspid Valve Regurgitation
Unknown Phase
2019-06 TRISCEND Study
Active, not recruitingNCT04221490
Start: 2020-05-06End: 2029-01-31Updated: 2026-05-08
Trisol System EFS Study
RecruitingNCT04905017
Start: 2022-03-02End: 2031-07-01Target: 30Updated: 2025-11-21
Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment
RecruitingNCT06033274
Start: 2023-10-05End: 2028-12-01Target: 800Updated: 2026-09-15
The TRICURE EFS Study
RecruitingNCT06506942
Start: 2024-09-11End: 2031-03-01Target: 15Updated: 2026-07-23
Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU)
RecruitingNCT06569602
Start: 2024-10-01End: 2033-09-30Target: 500Updated: 2026-09-04
The TRICURE EU Pivotal Study
RecruitingNCT06581471
Start: 2024-08-29End: 2030-12-30Target: 80Updated: 2026-04-15
Clinical Study of the inQB8 TTVR System (The MonarQ Study)
RecruitingNCT06611579
Start: 2025-06-01End: 2030-10-31Target: 50Updated: 2026-05-18
Characterization and Outcomes of Patients Screened for Transcatheter Tricuspid Valve Replacement
CompletedNCT06862765
Start: 2023-03-01End: 2024-06-30Updated: 2025-03-06
Robotic Transjugular Transcatheter Tricuspid Valve Replacement
RecruitingNCT07516145
Start: 2026-03-12End: 2028-03-31Target: 10Updated: 2026-09-18